US 12,391,737 B2
Soluble NPY2 receptor agonists
Peter Wilhelm Haebel, Mittelbiberach (DE); Albert Brennauer, Biberach an der Riss (DE); Stefan Peters, Biberach an der Riss (DE); Charlotte Stahl Madsen, Måløv (DK); and Søren Ljungberg Pedersen, Borup (DK)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Aug. 5, 2021, as Appl. No. 17/394,522.
Claims priority of application No. 20189966 (EP), filed on Aug. 7, 2020.
Prior Publication US 2022/0041678 A1, Feb. 10, 2022
Int. Cl. C07K 14/575 (2006.01); A61K 38/22 (2006.01); A61K 45/06 (2006.01); A61P 3/04 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/575 (2013.01) [A61K 38/22 (2013.01); A61K 45/06 (2013.01); A61P 3/04 (2018.01); A61K 38/00 (2013.01)] 18 Claims
 
1. A PYY analogue comprising:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.